Objectif The ability to recognize molecular processes using novel imaging techniques is of fundamental importance for medicine, biology and biochemistry in the 21st century. Non-invasive molecular imaging has gained widespread use in patient management of cancer, life-science and medical research, as well as drug discovery and development. The capability of non-invasive metabolic profiling is expected to impact dramatically patient management for socioeconomically relevant diseases. Spatially-resolved observation of metabolites will be key for enabling more accurate staging of diseases by direct assessment of the underlying impact on the metabolism. Quantification of, for example, the perturbation of the myocardial, tumor, or neural substrate metabolism will most likely revolutionize staging and management of diseases in cardiology, neurology, oncology and other fields. Building on novel quantum technology using nitrogen-vacancy in diamonds we have developed in first in the DIAMANT FET project, and continued the FET proactive project DIADEMS - DIAmond Devices Enabled Metrology and Sensing, we are developing an MRI-based breakthrough technology for enabling previously unachievable, highly sensitive quantification of metabolic imaging, enabling earlier diagnostic and personalized therapies, thus substantially improving patient management. However, research and development are not sufficient for attracting private investors and commercialization of a disruptive technology. In QUSMI we will understand the customer needs, reach out to strategic partners, consolidate our IP portfolio and strategy, and develop our business plan. Thus placing us in a position to attract private investors and commercialize the research technology into a product. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicineoncologyprostate cancermedical and health scienceshealth sciencespersonalized medicineengineering and technologymedical engineeringdiagnostic imagingmagnetic resonance imagingmedical and health sciencesbasic medicineneurology Programme(s) H2020-EU.1.2. - EXCELLENT SCIENCE - Future and Emerging Technologies (FET) Main Programme H2020-EU.1.2.1. - FET Open Thème(s) FETOPEN-04-2016-2017 - FET Innovation Launchpad Appel à propositions H2020-FETOPEN-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-FETOPEN-4-2016-2017 Régime de financement CSA - Coordination and support action Coordinateur NVISION IMAGING TECHNOLOGIES GMBH Contribution nette de l'UE € 77 562,30 Adresse WOLFGANG-PAUL-STRASSE 2 89081 ULM Allemagne Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Baden-Württemberg Tübingen Ulm, Stadtkreis Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 77 562,50 Participants (1) Trier par ordre alphabétique Trier par contribution nette de l'UE Tout développer Tout réduire UNIVERSITAET ULM Allemagne Contribution nette de l'UE € 18 900,00 Adresse HELMHOLTZSTRASSE 16 89081 Ulm Voir sur la carte Région Baden-Württemberg Tübingen Ulm, Stadtkreis Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 18 900,00
